ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclin...( ADVENTRX Presents Results at 2007 AA...)

ADVENTRX Presents Results at 2007 AACR-NCI-EORTC International Conference

SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today it presented preclinical results demonstrating that ANX-514, the company's docetaxel emulsion product candidate, reduced hypersensitivity reactions without impacting pharmacokinetics or antitumor activity when compared to Taxotere(R) (docetaxel). The results were presented at the American Association of Cancer Research (AACR), National Cancer Institute (NCI) and European Organization and Treatment of Cancer (EORTC) International Conference "Molecular Targets and Cancer Therapeutics" in San Francisco on October 25, 2007 by Mark J. Cantwell, Ph.D., vice president, research and development. Docetaxel is an anti-cancer agent that is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers, and is marketed under the brand name Taxotere(R). Annual sales of Taxotere in 2006 were approximately $2.2 billion.

"We feel the reduced hypersensitivity reactions associated with ANX-514 would be a benefit to patients and a way to differentiate ANX-514," stated Evan M. Levine, chief executive officer of ADVENTRX. "We remain focused on initiating a marketing-enabling clinical trial of ANX-514 later this year, pending appropriate regulatory clearances."

In an established animal model, anaphylactoid clinical reactions were observed following Taxotere administration, including decreased respiration, swelling and tremors. Furthermore, decreases in blood pr
'/>"/>